This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Teriparatide, abaloparatide, and LA-PTH showed comparable PTH1R downstream signaling (cAMP, calcium, SIK, gene expression) in vitro, with abaloparatide uniquely showing faster receptor recycling after washout.
Why it matters
Understanding why similar peptide drugs have different clinical effects is key to designing better bone therapies. If the difference is pharmacokinetic rather than signaling-based, it changes how we optimize these drugs.
The numbers in context
3 ligands; no difference in cAMP, calcium, β-arrestin, SIK2, gene expression; abaloparatide faster receptor recycling; comparable at all tested concentrations
How the study worked
Lab study comparing three PTH1R ligands across multiple cell-based signaling assays: receptor internalization, beta-arrestin recruitment, intracellular calcium, cAMP, SIK2 phosphorylation, substrate dephosphorylation, and gene expression changes.
Who was studied
Cell-based comparison of three PTH1R peptide ligands across multiple signaling assays
What this study cannot tell us
In vitro study only. Cell-based assays may not capture the full complexity of PTH1R signaling in bone cells in vivo. Only short-term signaling was measured. Pharmacokinetic differences were proposed but not tested.
Read the original research
Comparable Initial Engagement of Intracellular Signaling Pathways by Parathyroid Hormone Receptor Ligands Teriparatide, Abaloparatide, and Long-Acting PTH.
JBMR plus, 5(5), e10441
Citation
Sato, Tadatoshi; Verma, Shiv; Khatri, Ashok; Dean, Thomas; Goransson, Olga; Gardella, Thomas J; Wein, Marc N. (2021). Comparable Initial Engagement of Intracellular Signaling Pathways by Parathyroid Hormone Receptor Ligands Teriparatide, Abaloparatide, and Long-Acting PTH.. JBMR plus, 5(5), e10441. https://doi.org/10.1002/jbm4.10441